Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain
Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman
Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman
View: Text | PDF
Research Article Neuroscience

Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain

  • Text
  • PDF
Abstract

A critical response to lysosomal membrane permeabilization (LMP) is the clearance of damaged lysosomes through a selective form of macroautophagy known as lysophagy. Although regulators of this process are emerging, whether organ- and cell-specific components contribute to the control of lysophagy remains incompletely understood. Here, we examined LMP and lysophagy in Niemann-Pick type C (NPC) disease, an autosomal recessive disorder characterized by the accumulation of unesterified cholesterol within late endosomes and lysosomes, leading to neurodegeneration and early death. We demonstrated that NPC human fibroblasts show enhanced sensitivity to lysosomal damage as a consequence of lipid storage. Moreover, we described a role for the glycan-binding F-box protein 2 (Fbxo2) in CNS lysophagy. Fbxo2 functions as a component of the S phase kinase-associated protein 1–cullin 1–F-box protein (SKP1-CUL1-SCF) ubiquitin ligase complex. Loss of Fbxo2 in mouse primary cortical cultures delayed clearance of damaged lysosomes and decreased viability after lysosomal damage. Moreover, Fbxo2 deficiency in a mouse model of NPC exacerbated deficits in motor function, enhanced neurodegeneration, and reduced survival. Collectively, our data identified a role for Fbxo2 in CNS lysophagy and establish its functional importance in NPC.

Authors

Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman

×

Figure 6

Fbxo2 localizes to damaged lysosomes.

Options: View larger image (or click on image) Download as PowerPoint
Fbxo2 localizes to damaged lysosomes.
(A) Ctrl and I1061T human fibrobla...
(A) Ctrl and I1061T human fibroblasts were transfected with HA-FBXO2, then treated with Veh or 1 mM LLOMe for 1 hour and stained for HA and Gal3. Colocalization is indicated by yellow staining in merged image. Mander’s coefficients: 0.80 (Ctrl) and 0.81 (I1061T). (B) I1061T human fibroblasts were electroporated with HA-FBXO2 and, after 48 hours, treated with 2 mM LLOMe for 2 hours. Lysates were immunoprecipitated with either HA antibody or Ctrl IgG. Arrowheads at approximately 50kD and approximately 25kD indicate immunoglobulin heavy and light chains, respectively. Asterisk denotes a nonspecific band detected by the LAMP2 antibody. (C) WT primary cortical cultures were transfected with HA-FBXO2 and treated with Veh or 2 mM LLOMe for 1 hour on D9IV. Cell were stained for HA and NeuN. Fbxo2, F-box protein 2; Ctrl, control; Veh, vehicle; LLOMe, L-leucyl-L-leucine methyl ester; Gal3, galectin-3.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts